Source: Annual Congress 2012 - Environmental exposure and other risk factors for airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Koskela, A. Kallio, H. Kupiainen, A. Lindqvist, M. Kilpeläinen, J. Pitkäniemi, V. Kinnula, T. Laitinen (Espoo, Finland). Individual decline of FEV1 show diversity in COPD. Eur Respir J 2012; 40: Suppl. 56, 3397

Member's Comments

No comment yet.

Related content which might interest you: Re-assessing the importance of FEV1 decline Source: Eur Respir Monogr 2015; 69: 134-142 Year: 2015 Exacerbation frequency and FEV1 decline of COPD: is it geographic? Source: Eur Respir J 2014; 43: 1220-1222 Year: 2014 Polymorphisms in surfactant proteins and FEV1 decline and development of COPD in the general population Source: Eur Respir J 2006; 28: Suppl. 50, 143s Year: 2006 Changes in spirometry (FVC and FEV1) in a closed population of COPD patients using new standarized values for Mexican people Source: Eur Respir J 2003; 22: Suppl. 45, 69s Year: 2003 FEV1 decline in occupational asthma Source: Eur Respir J 2003; 22: Suppl. 45, 488s Year: 2003 The evaluation of different factors that cause FEV1 decline in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 135s Year: 2001 Frequent exacerbations in COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006 FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Biomarkers to predict FEV1 decline in smokers and early-onset COPD. Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases Year: 2020 Tiotropium: COPD exacerbations and decline in FEV1 Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 Rate of FEV1 decline by FEV1 percent predicted in UPLIFT® and TIOSPIR® Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Decline in FEV1 is faster with frequent exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001 Association between weight loss and decline in FVC in patients with IPF Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 The relationship between long-term correlations (self-similarity) in PEF and FEV1 in COPD Source: Annual Congress 2012 - New issues in pulmonary function Year: 2012 Improved survival with increased IC/TLC ratio, DLCO and FEV1 in an analysis of a COPD pulmonary function database Source: Annual Congress 2011 - Lung and airway function Year: 2011 Duration and frequency of spirometry needed to accurately reflect longitudinal change of FEV1 in COPD Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases Year: 2021 Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Maximally attained level of FEV1 and FEV1 decline determine airway hyperresponsiveness in adults Source: Eur Respir J 2003; 22: Suppl. 45, 17s Year: 2003 The relationship between peak expiratory flow rate (PEFR) and forced expiratroy volume in the first second (FEV1) at low levels of FEV1. Implications for the assessment of COPD (chronic obstructive pulmonary disease) in primary care Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002 Comparison of spirometric z-scores with FEV1 percent prediction in predicting exacerbations in elderly COPD patients Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016